Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib versus dupilumab in adults with moderate to severe atopic dermatitis
NL-OMON49672Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of upadacitinib and dupilumab, sponsored by AbbVie Inc. Started Nov 2019; status: completed.
02
Drugs
upadacitinibdupilumab
Beyond the preview
Go deeper on NL-OMON49672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49672.